CervoMed Inc. (CRVO)
NASDAQ: CRVO · IEX Real-Time Price · USD
15.85
-0.27 (-1.67%)
Jul 2, 2024, 4:30 PM EDT - Market closed
Company Description
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders.
Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.
The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
CervoMed Inc.
Country | United States |
Founded | 2001 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Dr. John J. Alam M.D. |
Contact Details
Address: 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 United States | |
Phone | (617) 744-4400 |
Website | cervomed.com |
Stock Details
Ticker Symbol | CRVO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001053691 |
Employer ID | 30-0645032 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. John J. Alam M.D. | Co-Founder, Chief Executive Officer, President and Director |
Dr. Sylvie L. Gregoire Pharm.D. | Co-Founder and Director |
William Robert Elder J.D. | General Counsel, Corporate Secretary and Acting Principal Financial Officer |
Dr. Robert J. Cobuzzi Jr., Ph.D. | Chief Operating Officer and Director |
Dr. John William Tanner Ph.D. | Chief Financial Officer (Leave of Absence) |
Kelly Blackburn M.H.A. | Senior Vice President of Clinical Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 14, 2024 | 424B3 | Prospectus |
Jun 14, 2024 | 8-K | Current Report |
Jun 6, 2024 | 424B3 | Prospectus |
Jun 5, 2024 | EFFECT | Notice of Effectiveness |
May 30, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
May 20, 2024 | 8-K | Current Report |
May 15, 2024 | 8-K | Current Report |
May 14, 2024 | 10-Q | Quarterly Report |
May 10, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Apr 29, 2024 | DEF 14A | Other definitive proxy statements |